Invectys Therapeutics
Houston
About Invectys Therapeutics
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by Pierre Langlade Demoyen and Simon Wayne-Hobson and is based in Paris. Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $64.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2020)
- Website: invectys.com
- Phone: 585-278-3001
Industries & Categories
Biopharma, Biotechnology, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/invectys-therapeutics-54664 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.